Literature DB >> 35434510

Stent angioplasty for coronary compression syndrome related to prosthetic aortic valve.

Clément Servoz1,2, Anthony Matta1,2,3, Didier Carrié1,2, Stephanie Blanco1,2.   

Abstract

Entities:  

Year:  2022        PMID: 35434510      PMCID: PMC9007425          DOI: 10.1093/ehjcr/ytac133

Source DB:  PubMed          Journal:  Eur Heart J Case Rep        ISSN: 2514-2119


× No keyword cloud information.

Case presentation

A 76-year-old woman was admitted for surgical aortic valve replacement for severe aortic valve stenosis and left atrial appendage occlusion. The pre-operative coronary angiography showed patent coronary arteries with anomalous origin of the left circumflex (LCX) arising as a side branch from the right coronary artery ( and ). The surgery was successfully performed without complications and a bioprosthetic Edwards Perimount aortic valve of 21 mm has been implanted. Four days after surgery, the patient developed an acute respiratory distress requiring 3 L of oxygen with positive troponin level that rises from 1800 to 2100 ng/L (normal range <14 ng/L). The transthoracic echocardiography (TTE) showed new onset hypokinaesia of the lateral myocardial wall and 12-lead electrocardiogram (EKG) showed significantly depressed ST-segment on infero-lateral leads. She was diagnosed with non-ST-elevation myocardial infarction (NSTEMI) and underwent emergent coronary angiography which revealed subocclusive stenosis of the LCX related to an extrinsic compression by the bioprosthetic aortic valve ( and ). On observing the clinical context and acute setting of NSTEMI, we decided to proceed with percutenaous coronary intervention (PCI) and stent implantation rather than re-do surgery. After crossing the obstructive lesion via a guidewire, we dilated a 2 mm × 15 mm balloon and deployed a 3 mm × 22 mm drug-eluting stent. Then, a post-dilation via a 3 mm × 12 mm non-compliant balloon permits to alleviate the residual in-stent stenosis ( and ). We note instant improvement of the clinical condition, normalization of EKG abnormalities, reduction in troponin level, and a good outcome in completely asymptomatic patient with normal TTE at 6 months of follow-up. (A and B) Pre-operative coronary angiograms showed patent left coronary arteries and right coronary artery with anomalous origin of left circumflex artery. (C and D) Post-operative coronary angiograms showed a subocclusive stenosis of the left circumflex coronary successfully treated by (E and F) percutaneous stent angioplasty. The risk of coronary compression is particularly reconsidered before transcatheter pulmonary valve implantation and represents the major contra-indication.[1,2] Data from the literature have identified the anomalous course of coronary arteries as independent risk factor.[2] The appropriate management of coronary compression syndrome is not well defined but establishment of normal blood flow is the main purpose. Herein, we report on the feasibility of PCI despite the technical challenges and risk of restenosis (11%),[3] especially in high-surgical-risk patients. All authors have contributed equally for this manuscript.
  3 in total

1.  Myocardial Ischemia caused by a coronary anomaly: left circumflex coronary artery arising from right sinus of valsalva.

Authors:  Mustafa Aydin; Ali Ozeren; Irfan Peksoy; Mehmet Cabuk; Mehmet Bilge; Aydin Dursun; Mehmet Ali Elbey
Journal:  Tex Heart Inst J       Date:  2004

2.  Utility of CT Angiography for the Prediction of Coronary Artery Compression in Patients Undergoing Transcatheter Pulmonary Valve Replacement.

Authors:  Elizabeth Rinaldi; Soraya Sadeghi; Saurabh Rajpal; Brian A Boe; Curt Daniels; John Cheatham; Sanjay Sinha; Daniel S Levi; Jamil Aboulhosn
Journal:  World J Pediatr Congenit Heart Surg       Date:  2020-05

3.  Risk of coronary artery compression among patients referred for transcatheter pulmonary valve implantation: a multicenter experience.

Authors:  Brian H Morray; Doff B McElhinney; John P Cheatham; Evan M Zahn; Darren P Berman; Patrick M Sullivan; James E Lock; Thomas K Jones
Journal:  Circ Cardiovasc Interv       Date:  2013-09-24       Impact factor: 6.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.